Close Menu

NEW YORK (GenomeWeb) – NanoString Technologies said after the close of the market on Monday that its preliminary second quarter revenues grew about 11 percent year over year, exceeding previous guidance.

The company also announced a $50 million underwritten public offering of its common stock, pursuant to an existing shelf registration statement. In connection with the offering, NanoString said it also expects to grant underwriters a 30-day option to purchase up to $7.5 million worth of additional common shares.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.